|
Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study. |
|
|
Honoraria - Bristol-Myers Squibb; Janssen; Pfizer; Roche; Sanofi |
Research Funding - Janssen; Sanofi |
Travel, Accommodations, Expenses - Bayer; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Janssen-Cilag |
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Bristol-Myers-Squib; Janssen Oncology; Merck Serono; Pfizer; Roche; Sanofi |
Speakers' Bureau - Bayer; Janssen Oncology; Pfizer |
Research Funding - Genzyme |
|
|
Research Funding - Bayer; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer; Janssen; Sanofi |
|
|
Research Funding - Bayer; Janssen; Sanofi |
|
|
Honoraria - Bayer; Janssen; Janssen |
|
|
Speakers' Bureau - Astellas Pharma |
Travel, Accommodations, Expenses - Bayer; Trinetx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - IPSEN; Janssen Oncology |
Travel, Accommodations, Expenses - BMS |
|
|
Honoraria - Bristol-Myers Squibb; IPSEN,; Novartis; Pfizer; SERVIER |
Speakers' Bureau - Bristol-Myers Squibb; IPSEN,; SERVIER |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; IPSEN,; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |